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BACKGROUND: Various aspects of medication adherence and health-related quality of life (HRQOL)
have been studied in subjects with COPD. Nevertheless, little is known about the association between
these factors. The aim of this study was to undertake a systematic review of the published literature
focusing on the relationship between medication adherence and HRQOL in COPD. METHODS: A
systematic literature search of English language articles was conducted in April 2013 using MEDLINE.
No publication date limits were defined. All of the included studies were assessed for quality. RESULTS:
Seven studies were included in the review. Three of the assessed studies found no correlation, and 3
studies described positive and 2 studies reported negative associations between medication adherence
and HRQOL. The results indicate that an improved HRQOL may be a trigger for non-adherence in
patients with COPD. CONCLUSIONS: The relationship between medication adherence and HRQOL
may be dual. The effect of medication adherence on HRQOL might be a consequence of the effectiveness
of therapy and the negative effects (ie, side effects, daily life limitation of therapy, social stigma) that it
can generate. HRQOL might also influence the patterns of patients’ drug use, as an increased HRQOL
might trigger non-adherence. The dynamics between adherence and HRQOL might differ over time, as
the negative effects of medication non-adherence might become dominant in the long term. Key words:
chronic obstructive pulmonary disease; COPD; medication adherence; medication compliance; quality of life;
patient outcome assessment; respiratory therapy. [Respir Care 2015;60(2):297–303. © 2015 Daedalus Enter-
prises]
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Introduction
COPD is a major public health problem.1,2 The preva-
lence of COPD is increasing worldwide, resulting in a
substantial economic burden.3
Medication adherence “refers to the act of conforming
to the recommendations made by the provider with respect
of timing, dosage and frequency of medication taking.”4
Medication non-adherence is common in COPD.5 Non-
adherence reduces the clinical benefit of the therapy and
accounts for many of the observed differences between the
efficacy reported in randomized controlled trials (RCTs)
and the effectiveness of the drug treatment achieved in
real-world conditions. In RCTs, conditions are highly con-
trolled, and the stringent follow-up protocol limits the oc-
currence of medication non-adherence; therefore, non-ad-
herence rates derived from RCTs do not reflect an objective
picture of medication adherence. Although the average
rates of adherence to COPD medication in RCTs have
been estimated to be 70–90%, in real-world conditions,
these rates are only in the range of 20–60%.5 The discon-
tinuation of COPD therapy contributes to the increased
frequency of exacerbations, number of hospitalizations,
and mortality rate.6-8
COPD impairs the health-related quality of life (HRQOL)
markedly; patients experience substantial limitations in
their daily life.9 HRQOL, one of the most important pa-
tient-reported outcomes, truly reflects the individual’s self-
report on health status and well-being.10
Medication adherence and HRQOL are 2 important in-
dicators in determining the success of drug treatments.
Although adherence and HRQOL have been studied in-
tensively in COPD, less is known about the association
between these factors.
The aim of this research was to undertake a systematic
review of the published literature to gain a better under-
standing of the relationship between medication adherence
and HRQOL in patients with COPD. Our hypothesis was
that the association between medication adherence and
HRQOL is dual. Therefore, the objective of this study was
to evaluate not only the effect of medication adherence on
HRQOL but also the impact of HRQOL on medication
adherence. To our knowledge, no comprehensive review
has been published on this topic to date.
Methods
Literature Search and Eligibility Criteria
A systematic literature search was conducted in April
2013 using MEDLINE (via PubMed) with the following
search string: (compliance OR adherence OR persistence
OR non-compliance OR non-adherence OR non-persis-
tence OR noncompliance OR nonadherence OR nonper-
sistence OR treatment acceptance OR concordance) AND
quality of life AND (chronic obstructive pulmonary dis-
ease OR COPD). No publication date limits were defined.
The search results were considered in 2 steps. Initially,
the titles and abstracts of all articles were screened; those
deemed relevant were analyzed in full. Additionally, the
references of the relevant articles were screened for addi-
tional eligible studies. The literature screening was con-
ducted by 2 independent reviewers (TA and PD). No ma-
jor disagreements between the reviewers occurred.
The reasons for exclusion in both steps were (1) the
article was not written in English; (2) the article was not
published in a peer-reviewed journal; (3) the article was an
editorial, letter, case report, or review; (4) the article was
not related to COPD; (5) the article was related to oxygen
therapy; (6) the article had not evaluated the association
between medication adherence/compliance/persistence and
HRQOL in COPD; or (6) the article had not reported the
results of studies conducted in real-world settings.
The data extraction focused on and was limited to find-
ings relevant to the research topic. The following infor-
mation was extracted from each study: (1) the first author
and year of publication, (2) the country, (3) the study
design, (4) the study population characteristics (size, per-
cent male, mean age, percent-of-predicted FEV1, COPD
stage), (5) the medication therapy, (6) the method of mea-
suring and defining adherence, (7) the method of measur-
ing HRQOL, (8) the evaluated association between med-
ication adherence and HRQOL, (9) the statistical method(s)
used, and (10) the results.
Quality Assessment of the Included Studies
For quality assessment of the included studies, the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) checklist for cohort, case con-
trol, and cross-sectional studies was used.11 All studies
were independently assessed by TA and PD; disagree-
ments were resolved by A´ M. The results for each study
were summarized as the percentage of the fulfilled criteria.
The criteria that were not applicable to a study were ex-
cluded from the quality assessment.
Results
Search Results
The database search resulted in 245 hits. The screening
of the titles and abstracts identified 21 potentially eligible
articles. After reviewing the relevant full texts, 7 studies
were finally included in the systematic review. No addi-
tional record was identified through a manual search of the
references of the relevant articles. Figure 1 shows the break-
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down of when and for what reason records were excluded
from the review.
Five studies were prospective cohort studies,12-16 and 2
cross-sectional studies17,18 were also included. The earliest
study dated from 1995,16 and the most recent was pub-
lished in 2013.15 The included studies originated from Can-
ada and the United Sates,16 Hungary,17 Japan,15,18 The
Netherlands,14 and the United Kingdom.12,13 The popula-
tion size varied between 1112 and 98516 subjects, with a
mean age of 5814 to 7615 y. The general characteristics of
the reviewed studies are presented in Table 1.
Methodological Quality
The included studies fulfilled the STROBE criteria be-
tween 64%14 and 81%.16 Details of the quality assessment
are provided (see the supplementary materials at http://
www.rcjournal.com). The majority of the studies described
their scope, study design, settings, participants, variables,
and measurements adequately. Hesselink et al14 were the
only authors who did not clearly define the method for
measuring adherence. No study provided information on
missing data and how they dealt with. All of the reviewed
studies described their statistical methods in detail; how-
ever, there was only one study that undertook a sensitivity
analysis to examine the robustness of the results.16
Medication Adherence and HRQOL
Medication adherence was measured in all included stud-
ies, but none of these assessed persistence. Medication
adherence was analyzed by a self-reported question-
naire,12,14,16-18 counting the number of unused doses of
medication,15 or an electronic monitoring method.12,13,16
Turner et al16 and Bosley et al12 used a self-reported ques-
tionnaire and electronic monitoring for measuring adher-
ence simultaneously, but both groups considered the sub-
jects to be adherent based on the results of the electronic
monitoring only. Except for the studies conducted by
Mochizuki et al15 and Bosley et al,12 most studies defined
adherence as a dichotomous variable.
The questionnaires used to measure HRQOL differed
between the studies. In most studies, a disease-specific
instrument was used12-15,18; only 2 studies measured ge-
neric HRQOL.16,17 The disease-specific St George Respi-
ratory Questionnaire was the most commonly used quali-
ty-of-life instrument.12,13,15,18
The association between adherence and HRQOL was
evaluated in all included studies; however, only one study
explored the effect of medication adherence on HRQOL,12
and one explored the impact of HRQOL on adherence.17
Detailed information on the measurements of adherence
and HRQOL, the applied statistical methods, and the re-
sults on the association between adherence and HRQOL
are summarized in Table 2.
Discussion
A comprehensive review of the relationship between
medication adherence and HRQOL in patients with COPD
was missing from the literature. Only 7 relevant articles
were found through our systematic literature search. The
findings of the reviewed studies were heterogeneous; nev-
ertheless, some demonstrated that the relationship between
medication adherence and HRQOL may be dual and may
be affected by multiple factors.
Association Between Medication Adherence and
HRQOL
The evidence suggests that, in COPD, non-adherence to
medication may not have a clear negative impact on
HRQOL. Three studies14-16 found no correlation, whereas
3 studies12,13,18 described positive and 2 studies16,17 re-
ported negative associations between adherence and
HRQOL. This heterogeneity might be caused by several
factors, such as differences in study design, study popu-
Fig. 1. Flow diagram of the systematic literature search.
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lation, therapy, adherence measurement methods, and
HRQOL instruments.
Considering the fact that the different HRQOL ques-
tionnaires may assess different aspects of HRQOL, the
type of HRQOL questionnaire could significantly influ-
ence the association between adherence and HRQOL. In
the study conducted by Turner et al,16 3 different HRQOL
instruments were used: the Sickness Impact Profile mea-
sured the effect of illness on daily functioning, the Profile
of Mood States measured feelings and mood, and the Re-
cent Life Changes Questionnaire measured changes in life-
style. Turner et al16 found no correlation between adher-
ence and HRQOL measured by the Sickness Impact Profile
and Profile of Mood States; however, the non-adherent
subjects reported significantly higher HRQOL scores on
the Recent Life Changes Questionnaire. The number of the
included studies was limited, and the types of HRQOL
questionnaires were very heterogeneous in these; there-
fore, HRQOL could be used only in a broad sense to
interpret the association between medication adherence and
HRQOL. In this broad concept, HRQOL has been defined
as the patient’s subjective perception of the impact of the
disease and its treatment(s) on daily life, physical/psycho-
logical/social functioning, and well-being.19
The effect of medication adherence on HRQOL can be
derived from the effectiveness of the pharmacologic ther-
apy and the negative effects that it can generate. Medica-
tion adherence improves a patient’s HRQOL by reducing
the symptoms, disease progression, and frequency and se-
verity of exacerbations. Aside from the treatment-related
side effects, there might be other factors as well by which
adherence could impair a patient’s HRQOL, such as a
daily life limitation of therapy and the social stigma of
using inhalers in public. Patients with moderate-to-severe
COPD are generally treated with combination therapy, and
most respiratory medications are dosed several times daily.
Therefore, COPD treatment regimens might significantly
impact a patient’s daily life.17 Patients with COPD are
mostly treated with inhalation medication; however, the
perceived social stigma associated with using inhalers in
public might also affect HRQOL.20
Not only can adherence affect HRQOL, but HRQOL
may also impact medication adherence.21 A´ gh et al17 found
that an improved HRQOL was a trigger for non-adherence
in subjects with COPD. They suggested that a patient’s
decision to adhere and to what extent is a personal trade-
off between the benefits and negative effects of the ther-
apy at any given time, which is consistent with the view of
Table 1. Characteristics of the Included Studies
Reference Country Study Design(Follow-Up) Study Population Characteristics Medication Therapy
Ágh et al17 Hungary Cross-sectional study n  170; mean age, 64 y; 42% male;
FEV1, 64% of predicted; GOLD
stages I/II/III/IV, 23/52/21/4%
Short-acting and long-acting  agonists,
short-acting and long-acting
anticholinergics, inhaled
corticosteroids, theophylline,
combinations
Bosley
et al12
United Kingdom Prospective cohort
(4 wk)
n  11; mean age, 64 y; 36% male;
FEV1 % of predicted, ND; GOLD
stages I/II/III/IV, ND.
Bronchodilators (all by nebulizer)
Corden
et al13
United Kingdom Prospective cohort
(4 wk)
n  82; mean age, 65 y; 54% male;
FEV1 % of predicted, ND; GOLD
stages I/II/III/IV, ND
Short-acting and long-acting  agonists,
short-acting anticholinergics,
corticosteroids (all by nebulizer)
Hesselink
et al14
The Netherlands Prospective cohort
(2 y)
n  120 (COPD); mean age, 58 y;
58% male; FEV1, 61% of
predicted; GOLD stages I/II/III/IV,
ND
Anti-inflammatory agents
Mochizuki
et al15
Japan Prospective cohort
(12 wk)
n  44; mean age, 76 y; 73% male;
FEV1, 55% of predicted; GOLD
stages I/II/III/IV, 0/64/36/0%
Transdermal tulobuterol patch, inhaled
salmeterol
Takemura
et al18
Japan Cross-sectional study n  55; mean age, 69 y; 73% male;
FEV1, 68% of predicted; GOLD
stages I/II/III/IV, 24/54/16/1%
Long-acting muscarinic antagonists,
short-acting and long-acting 
agonists, inhaled corticosteroids
Turner
et al16
Canada,
United States
Prospective cohort
(1 y)
n  985; mean age, 61 y; 81% male;
FEV1, 41% of predicted; GOLD
stages I/II/III/IV, ND
Bronchodilators (all by nebulizer)
GOLD  Global Initiative for Chronic Obstructive Lung Disease
ND  not determined
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Bosley et al12 that adherence is related to the current health
status of the patient and is not dependent on previous
experience of illness. The initiation of a pharmacologic
therapy in newly diagnosed COPD patients might signif-
icantly improve their HRQOL; however, later, this HRQOL
improvement due to medical treatment might be smaller
and could be detected only in the long term.22 Therefore,
if patients have previously been treated for longer dura-
tions, the benefits from medication non-adherence might
temporarily outweigh the effects of the disease deteriora-
tion in the short term. The dynamics between adherence
and HRQOL might differ over time. The negative effects
of a patient’s non-adherence could become more and more
significant over a longer time horizon.
Psychiatric disorders such as depression and anxiety are
highly prevalent in patients with COPD.23 Psychiatric co-
morbidities influence the relationship between medication
adherence and HRQOL. Evidence suggests that depression
Table 2. Association of Medication Adherence and HRQOL Based on the Results of the Included Studies
Ágh et al17 Bosley et al12 Corden et al13 Hesselink et al14 Mochizuki et al15 Takemura et al18 Turner et al16
Adherence
Measurement Self-reported
questionnaire
(MMAS-4)
Electronic monitoring,
self-reported
questionnaire
Electronic monitoring Self-reported
questionnaire
Counting number
of unused
doses of
medication
Self-reported
questionnaire
Electronic monitoring,
self-reported
questionnaire
Variable Dichotomous Dichotomous,
continuous
Dichotomous Dichotomous Continuous Dichotomous Dichotomous
Threshold of
adherence
 3 scores Subjects on regimens
of up to 4 times
daily, taking
 70% of
treatment; subjects
on regimens of up
to 5 times daily,
taking  60% of
treatment
Taking  70% of
treatment
Not reported Not applicable  4 scores  25 min of nebulizer
use/d
HRQOL EQ-5D-3L SGRQ SGRQ QOL-RIO SGRQ SGRQ SIP, POMS, RLCQ
Evaluated
association
Adherence 7
HRQOL
Yes Yes Yes Yes Yes Yes Yes
Adherence 3
HRQOL
No Yes No No No No No
HRQOL 3
adherence
Yes No No No No No No
Statistical
methods
Univariate and
multivariate analyses
Univariate and
multivariate
analyses
Univariate analysis Univariate
analysis
Univariate
analysis
Univariate
analysis
Univariate analysis
Results (1) HRQOL negatively
correlated with
adherence (EQ-5D-
3L index scores). (2)
Multiple regression
analysis indicated
that an improved
HRQOL had a
significant negative
effect on adherence
(EQ-5D-3L index
scores).
Baseline: No
correlation existed
between %
adherence and
HRQOL (SGRQ).
At the 4-wk visit:
(1) Percent
adherence
correlated with an
improved HRQOL
(symptoms, impact,
and total SGRQ
scores).
(2) Multiple
regression analysis
indicated that %
adherence had a
significant positive
effect on HRQOL
(total SGRQ
scores).
Baseline: No
correlation existed
between adherence
and HRQOL
(SGRQ).
At the 4-wk visit:
Adherence
correlated with an
improved HRQOL
(symptoms, impact,
and total SGRQ
scores).
During the 2-y
follow-up: No
significant
correlation
existed
between
adherence and
HRQOL
(QOL-RIO
scores).
After the 12-wk
follow-up
period: No
significant
correlation
existed
between %
adherence (to
either
medication)
and HRQOL
(SGRQ total
scores).
Mean adherence
score showed
significant
correlation
with an
improved
HRQOL
(total SGRQ
scores and
subscores
expected for
activities).
No correlation existed
between adherence
and HRQOL
measured with
POMS and SIP. A
significant negative
correlation existed
between adherence
and HRQOL
measured with
RLCQ.
HRQOL  health-related quality of life
MMAS 4 4-Item Morisky Medication Adherence Scale
SGRQ  St George Respiratory Questionnaire
QOL-RIO  Quality of Life in Respiratory Illness Questionnaire
SIP  Sickness Impact Profile
POMS  Profile of Mood States
RLCQ  Recent Life Changes Questionnaire
Adherence7HRQOL  correlation between medication adherence and HRQOL
Adherence3 HRQOL  effect of medication adherence on HRQOL
HRQOL3 adherence  effect of HRQOL on medication adherence
MEDICATION ADHERENCE AND HRQOL IN SUBJECTS WITH COPD
RESPIRATORY CARE • FEBRUARY 2015 VOL 60 NO 2 301
is linked to non-adherence and HRQOL impairment.12,24
Therefore, a patient’s psychiatric comorbidity might affect
the relationship between these factors.
Future Studies and Recommendations
Overall, the methodology of the reviewed studies was
not entirely appropriate to evaluate the relationship be-
tween adherence and HRQOL in COPD patients; there-
fore, it would be important to develop recommendations
for future studies in this area.
In the long term, evidence from real-world settings could
provide more reliable data regarding the association be-
tween medication adherence and HRQOL compared with
RCTs. Real-world studies assess effectiveness in unse-
lected populations; subjects are under routine care, taking
open-label treatment, with no additional visits, allowing an
objective assessment of medication adherence. A study in
real-word settings, preferably with a minimum of a 1-y
study period and regular screening visits (eg, quarterly),
would be desirable.
There are a number of ways to measure adherence; nev-
ertheless, there is no accepted standard because each method
has its strengths and limitations.5 The easiest way to assess
adherence is to collect information from the subjects them-
selves through questionnaires. However, self-reporting
methods might overestimate adherence. The retrospective
analysis of prescription refill data is rapid and inexpensive
but does not provide information on medication intake or
inhaler use directly. Pill counting and canister weighing
are widely used methods of adherence assessment, espe-
cially in clinical trials; pill counting is limited to oral med-
ications, but canister weighing can be used for inhalers as
well. These approaches assess only the quantity of the
medication removed from the canister without any indica-
tion of ingestion or inhalation. Electronic monitoring meth-
ods for measuring adherence can provide more objective
data about medication use than the aforementioned meth-
ods. Pill bottles, inhalers, and nebulizers can all be fitted
with electronic recording devices. The evidence suggests
that although the underuse of medications seems to be one
of the largest problems in the management of COPD, over-
use is also common.5 To be able to separate and identify
both types of medication non-adherence, it would be of
great value to define adherence as a categorical variable
(ie, full adherer, partial adherer, partial non-adherer, over-
user) or a continuous variable instead of as a dichotomous
variable (adherent vs non-adherent).
Regarding the assessment of HRQOL, generic and dis-
ease-specific instruments may capture complementary in-
formation. Disease-specific instruments seem to be more
sensitive for the clinical measures of COPD. However,
generic questionnaires capture more broad aspects of health
but are less sensitive to clinical changes.25 For this reason,
the optimal situation would be for generic (eg, EQ-5D
health questionnaire) and disease-specific (eg, St George
Respiratory Questionnaire) measures to be used simulta-
neously to monitor a patient’s HRQOL.
To understand fully the dynamics of adherence and
HRQOL, it would be important to also assess how other
factors such as disease symptoms, disease severity, side
effects, and the patient’s satisfaction (understanding the
social and psychological impact of medical therapy) and
psychological status (eg, depressive symptoms, anxiety)
influence the nature of their relationship. The evidence
suggests that there is only a weak correlation between lung
function and HRQOL.26 As recommended by the Global
Initiative for Chronic Obstructive Lung Disease (http://
www.goldcopd.org/uploads/users/files/GOLD_Report_2013
Feb13.pdf, Accessed October 1, 2013), the assessment of
disease severity should be based not only on a spirometric
assessment but also on the patient-reported outcome instru-
ments (eg, breathlessness measurement using the Modified
British Medical Research Council Questionnaire, COPD As-
sessment Test, Clinical COPD Questionnaire, and Borg scale).
A univariate statistical analysis is important but not suf-
ficient for evaluating the association between medication
adherence and HRQOL. Therefore, a univariate analysis
needs to be complemented with a multivariate analysis.
Limitations
Our findings should be considered in light of the fol-
lowing limitations. Our systematic review identified only
studies published in English and in peer-reviewed jour-
nals, and our search was limited to MEDLINE. We in-
cluded studies that evaluated the relationship between med-
ication adherence and HRQOL. However, we acknowledge
the importance of oxygen therapy and other non-pharma-
cologic interventions in COPD, such as physical activity,
nutrition, and other lifestyle recommendations. The asso-
ciation between adherence to these interventions and
HRQOL would also require evaluation.
Conclusions
The association between medication adherence and
HRQOL may be dual. The effect of medication adherence
on HRQOL might be a consequence of the effectiveness of
the therapy and the negative effects (ie, side effects, daily
life limitation of therapy, social stigma) that it can gener-
ate. In contrast, the level of HRQOL, may also influence
the patterns of patients’ drug use; an increased HRQOL
may trigger non-adherence. In addition, the dynamics be-
tween adherence and HRQOL might differ over time. In
the short term, the benefits could be dominant, whereas in
the long term, the negative effects of medication non-
adherence might become dominant. There is a clear need
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for rigorous research to better understand the dynamics
between adherence and HRQOL in COPD. Such data would
be critically important for optimal COPD management and
should also be considered when integrating medication
adherence into health-economic evaluations (eg, adher-
ence interventions).
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